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Evaporative  crystallization  is  widely  applied  in several  industrial  processes,  including  the  pharmaceutical
industry.  Microwave  irradiation  can  signiﬁcantly  speed  up  solvent  evaporation  in these crystallization
processes,  resulting  in  reduced  particle  size  due  to  rapid  crystallization.  A single-mode  microwave  setup
was used  for  evaporative  crystallization  of the model  active  pharmaceutical  ingredient,  niﬂumic  acid,  and
the polymer,  polyvinylpirrolidone  (PVP).  Production  of  crystals  by  microwave  irradiation  offers  a modern
way for drug  formulation,  and  by reducing  the particle  size  the dissolution  rate  and  bioavailability  of  the
active  pharmaceutical  ingredient  can be enhanced.  In this  study,  a 2.5-fold  increase  in the  dissolutionvaporative crystallization
iﬂumic acid
hysico-chemical analysis
morphous solid dispersion
rate  of  the  produced  niﬂumic  acid  crystals  was  observed  compared  to  the  dissolution  rate  of  the  original
drug  in 120  min. When  niﬂumic  acid  was  produced  together  with  the  PVP  in  the  microwave  system,
an  amorphous  solid  dispersion  was  created  with  particles  in the nano-size  range, which  showed  a 5-
fold  increase  in dissolution  rate  in  120  min  compared  to the dissolution  of  the  crystalline  niﬂumic  acid
samples  created  by the  microwave  irradiation  in the  absence  of  PVP.
© 2014  Elsevier  B.V.  All  rights  reserved.. Introduction
Solving bioavailability problems of new active pharmaceutical
ngredients is a major challenge for the pharmaceutical indus-
ry, since nearly half of the new active substances in the pipeline
re either insoluble or poorly soluble in water [1–3]. As the
rystallization method determines the product properties, it is
ossible to increase the dissolution rate and achieve a higher
ioavailability of drugs by selecting proper crystallization condi-
ions [4–7].
Niﬂumic acid (NIF) is an important active pharmaceutical ingre-
ient with anti-inﬂammatory activity accompanied by an analgesic
ffect [8]. It is primarily used to treat different forms of rheuma-
ism and relieve other inﬂammatory states, the main side-effects
eing nausea or vomiting [9]. According to the Biopharmaceutics
lassiﬁcation System (BCS), NIF belongs to class II, a practically
ater-insoluble (26 g ml−1 at 25 ◦C), lipophilic and highly per-
eable compound [10]. To achieve optimal pharmacodynamic
roperties such as a rapid onset of the drug effect, fast dissolution is
mportant for this type of drug. In our earlier studies, the aim was to
∗ Corresponding author. Tel.: +31 015 2781447.
E-mail addresses: G.Stefanidis@tudelft.nl, geo.stefanidis@gmail.com
G.D. Stefanidis).
ttp://dx.doi.org/10.1016/j.jpba.2014.04.020
731-7085/© 2014 Elsevier B.V. All rights reserved.improve the solubility and dissolution rate, via the preparation of
ternary systems of NIF, cyclodextrin (CD) and polyvinylpyrrolidone
K-25 (PVP) in different NIF to CD to PVP ratios by physical mixing,
kneading, microwave irradiation and micronization [11–14]. PVP
acts as a stabilizer arresting the aggregation of small size drug parti-
cles; it also has sometimes a crystallization inhibition effect. Due to
its good solubility in a wide variety of organic solvents, it is particu-
larly suitable for the preparation of solid dispersions by the solvent
method, where the drug and PVP was  dissolved in an organic sol-
vent that was evaporated later by different drying methods (e.g.
spray-drying, vacuum, cold or hot dryer). The aim of the prepara-
tion of PVP solid dispersions is generally to transform the drug into
the amorphous form and thus to achieve faster dissolution. Disper-
sions containing crystalline areas exhibit biphasic release proﬁles,
with the amorphous areas dissolving quickly and the crystalline
areas slowly. The amorphous state may  also be introduced deliber-
ately to enhance the biopharmaceutical properties of the product
[15].
In our recent communication [16], the relationship between
size reduction and extremely high evaporation rate, caused by
microwave irradiation, was  shown. The physics of microwave heat-
ing are fundamentally different from those found in conventional
heating systems. Microwave offers a convenient, rapid and contact-
free method of heating without the need of a heat transfer surface
or heat transport ﬂuids.
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applied to induce electric conductivity on the surface of the sam-
ples. The air pressure was 1.3–13.0 MPa. Samples were ﬁxed onto a
metallic stub with double-sided conductive tape (diameter 12 mm,
Table 1
Composition of the samples prior to the microwave irradiation.
Sample NIF (mg) PVP (mg) Ethanol (mL)Fig. 1. Shematic drawing of the microwa
In the present paper, samples prepared by microwave-assisted
vaporative crystallization with and without the polymer, PVP, are
nalyzed. The microwave effects on crystal shape and crystal size
istribution are investigated with scanning electron microscopy.
he structure of the products is investigated using differential scan-
ing calorimetry and X-ray powder diffraction. Wettability and
n vitro dissolution rate proﬁles of the products are presented and
ompared with the manufacturer product.
. Materials and methods
.1. Materials
Niﬂumic acid (NIF) (2-[[3-(triﬂuoromethyl)phenyl]amino]-3-
yridinecarboxylic acid) was purchased from Richter Gedeon
harmaceuticals. Polyvinylpyrrolidone K-25 (PVP) was  from ISP
ustomer Service GmBH (Köln, Germany). For all the crystallization
rocesses the solution was prepared with 99.6% ethanol, purchased
rom Sigma–Aldrich.
.2. Methods
.2.1. Preparation procedure
.2.1.1. Microwave-assisted evaporative crystallization (MW).
00 mg  NIF was dissolved in 5 ml  ethanol. The solution was
njected into a quartz petri dish, which was placed into the cavity
f CEM Discover (Fig. 1). The magnetron generates a microwave
eld with a frequency of 2.45 GHz with a maximum microwave
ower of 300 W.  The metal wall between the cylindrical space
nd the waveguide is slotted. Through these slots electromag-
etic energy can be exchanged between the waveguide and the
ylindrical cavity. As the electromagnetic ﬁeld maximum is in the
iddle of the cavity, the sample was put on top of a 40 mm high
olystyrene cube, which had a hole in the middle allowing the
nfrared temperature sensor of the Discover instrument to record
emperatures. There were two different types of experiments
erformed. In one type, the maximum allowable power of the
evice (300 W)  was applied and held constant. In the other type,sisted evaporative crystallization setup.
the microwave power applied was  adjusted during the experiment
in order to keep the solution temperature constant at 70 ◦C. The
solvent was completely evaporated by microwave irradiation in
both cases. The procedure parameters were determined in our
earlier study [16].
2.2.2. Sample composition
Table 1 shows the composition of the investigated products. The
product designated in the text as NIF-MW refers to the niﬂumic
acid prepared with application of the constant microwave power
(300 W).  The product designated as NIF-MW-Tconst refers to the
niﬂumic acid prepared with application of microwave power at
constant temperature (70 ◦C) during the experiment. The NIF-PVP-
MW refers to the product prepared from a solution containing the
API, niﬂumic acid, and the excipient, PVP, dissolved, while a con-
stant microwave power (300 W)  was  applied. The ratio between
NIF and PVP was determined by preliminary experiments and data
from literature [17].
2.3. Analysis
2.3.1. Scanning electron microscopy (SEM)
The crystal size and shape were examined by scanning electron
microscopy (Hitachi S4700, Hitachi Scientiﬁc Ltd., Japan). A sput-
ter coating apparatus (Bio-Rad SC 502, VG Microtech, England) wasNIF 100 0 0
NIF-MW (300 W)  100 0 5
NIF-MW-Tconst (70 ◦C) 100 0 5
NIF-PVP-MW (300 W)  100 50 5
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microwave-assisted crystallization did not decrease. On the DSC
curve of NIF-PVP-MW sample, the melting point is absent and only
the glass transition temperature value of the sample (171.44 ◦C) can
be detected – indicating the amorphous character of the product.
Table 2
The mean diameter over volume (MV) with the standard deviation (SD).
Sample MV (m ± SD)8 N. Radacsi et al. / Journal of Pharmaceut
xon, Oxford Instruments, UK). Images were taken in secondary
lectron image mode between 10 and 15 kV acceleration voltage.
.3.2. Particle size distribution measurements
The particle size distribution of the produced crystals was  mea-
ured by two different ways. One measurement was performed by
 laser diffraction particle size analysis instrument (S3500 parti-
le size analyzer, Microtrac, USA) in dry mode. This instrument
ses three red laser diodes to accurately characterize particles. The
3500 is capable of measuring particle sizes from 0.02 to 2800
icrons, and around 0.5 g of material is enough for the measure-
ent.
The other method used was SEM images processed in the ImageJ
oftware environment [18]. Over 150 individual particle measure-
ents were made in at least ﬁve different images in order to
etermine the particle size accurately. Although less frequently
sed than TEM or dynamic light scattering, SEM image analysis is
n established method for nanoparticle size analysis [19].
.3.3. Differential scanning calorimetry (DSC)
DSC was employed to investigate the crystallization behavior
nd the melting behavior of the conventional and submicron-sized
IF. The DSC measurements were made with a Mettler Toledo
SC 821e thermal analysis system with the STARe thermal analysis
rogram V9.1 (Mettler Inc., Schwerzenbach, Switzerland). Approx-
mately 2–5 mg  of product was examined in the temperature range
etween 25 ◦C and 300 ◦C. The heating rate was 5 ◦C min−1. Argon
as used as a carrier gas, at a ﬂow rate of 10 l h−1 during the DSC
nvestigation.
The crystallinity index of the different NIF samples was  calcu-
ated from the heats of fusion: the ratio between the normalized
nthalpy of the NIF samples and the normalized enthalpy of the
onventional NIF indicates the product crystallinity [20].
.3.4. X-ray diffraction (XRD)
XRD was carried out to determine the crystalline form and
rystallinity of the produced materials. Samples were measured
ith a Bruker D2 diffractometer (Bruker AXS GmbH, Karlsruhe,
ermany). Data collection was carried out at room temperature
sing monochromatic Cu K1 radiation (  ˛ = 0.154060 nm)  in the 2
heta region between 3◦ and 50◦. For measurements directly after
rystallization, about 10 mg  of sample was put on a zero back-
round holder (Si single crystal 〈5 1 0〉 wafer) and placed into the
RD chamber.
.3.5. Wettability studies
The OCA Contact Angle System (Dataphysics OCA 20, Data-
hysics Inc., GmbH, Germany) was used to measure the wettability
f the carrier systems and products containing NIF. A small amount
0.15 g of powder) was compressed under a pressure of 1 ton by a
pecac hydraulic press (Specac Inc., USA). The wetting angles of
he pressings were determined after 4.3 l of distilled water had
een dropped onto the surface of the pressings. The change in
he wetting angle was registered from 1 to 25 s (minimum of 5
arallel numbers), using the circle ﬁtting method of the OCA Sys-
em. The method of Wu was applied, in which two  liquids with
nown polar ( lp) and dispersion ( ld) components are used for
easurement [21]. The solid surface free energy is the sum of the
olar (p) and non-polar (d) components and is calculated accord-
ng to the following equation:
4(ds 
d
l
) 4(ps 
p
l
)1 + cos )l =
ds + dl
+
ps + pl
here  is the contact angle, s is the solid surface free energy
nd  l is the liquid surface tension. The percentage polarity cand Biomedical Analysis 98 (2014) 16–21
be calculated from the p and  values: (p/) × 100. The liq-
uids used for our contact angle measurements were bidistilled
water (p = 50.2 mN  m−1, d = 22.6 mN  m−1) and diidomethane
(p = 1.8 mN m−1, d = 49 mN m−1). The results of the contact
angle measurements on the samples containing diiodomethane
as non-polar component and water as polar component provide
information on the surface free energies and polarities of NIF.
2.3.6. In vitro dissolution
The dissolution proﬁle of product samples containing equal
amounts of drug (14 mg  of NIF according to its therapeutic dose)
was determined using the modiﬁed paddle method. A phosphate
buffer solution (50 ml,  pH 1.2 ± 0.1) at 37 ± 0.5 ◦C was used as a
dissolution medium and the rotation speed of the paddles was
100 rpm. At certain time intervals, 2 ml  solution samples were
withdrawn and ﬁltered (cut-off 0.2 m,  Minisart SRP 25, Sarto-
rius, Germany) and the amount of dissolved drug was determined
spectrophotometrically by an ATI-Unicam UV2-100 UV/VIS spec-
trophotometer at 256 nm.  It is common practice to replace the
withdrawn samples with fresh medium. The dissolution of NIF is
pH-dependent. Both the solubility and the dissolution rate of NIF
are higher at pH values around pH 6.8–7.4 (intestinal pH) than at
pH 1.2 (gastric pH). In our dissolution studies pH 1.2 was  used.
3. Results and discussion
3.1. Micrometric properties
The changes in the product size and shape were revealed by the
SEM images (Fig. 2.). The NIF crystals had a smooth surface with
prismatic form, with a mean particle size of ∼80 m.  The character-
istic morphology of the NIF was also seen in the NIF-MW product.
Due to the rapid re-crystallization by the microwave irradiation
the mean size of the produced particles decreased from ∼80 m
to ∼25 m Table 2. When the temperature was  controlled, we
got slightly smaller particles (∼17 m)  compared to NIF-MW. In
addition, the morphology changed; more particles with an approx-
imate spherical shape were found according to Fig. 2C. In the case
of NIF-PVP-MW, the presence of PVP prevents the aggregation of
the produced round-shaped nano-sized NIF particles (∼200 nm).
According to Fig. 2D, PVP forms a carrier for the NIF nanocrystals
and prevents particle size growth and crystallization.
3.2. Structural characterization
DSC was  employed to investigate the melting points and crys-
tallinty of NIF before and after the crystallization process. Single
sharp endothermic peaks were observed (Fig. 3), corresponding
to the melting points of the manufacturer NIF (203.25 ◦C), NIF-
MW (203.67 ◦C) and NIF-MW-Tconst (203.92 ◦C), which remain
nearly equal. The crystallinity index calculations revealed that the
crystallinty of the NIF samples produced without the PVP via theNIF 80 ± 48
NIF-MW 25 ± 19
NIF-MW-Tconst 17 ± 11
NIF-PVP-MW 0.199 ± 0.17
N. Radacsi et al. / Journal of Pharmaceutical and Biomedical Analysis 98 (2014) 16–21 19
Fig. 2. SEM pictures of the manufacturer NIF sample and produced samples.
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out the PVP. It is shown in Table 3 that signiﬁcantly lower contactFig. 3. DSC curves of NIF and product samples.
XRPD was used to examine the crystalline phase of the prod-
cts. The characteristic peaks of NIF are the 2 values of 8.2, 12.88,
6.16, 23.18 and 25.4. The XRPD patterns of both the NIF-MW and
IF-MW-Tconst show a crystalline character (Fig. 4.) with the char-
cteristic peaks of the original NIF, indicating that the NIF remained
he same form after the microwave treatment.
The NIF-PVP-MW sample did not show a crystalline fraction;
he curve shows the amorphous form of the product. To sum-
arize the structural characterizations, we can conclude that
icrowave-assisted evaporation using PVP results in amorphousFig. 4. XRPD patterns of the prepared NIF samples.
submicron-sized particles of NIF compared to the crystallization
process without the excipient (NIF-MW/NIF-MW-Tconst).
3.3. Wettability and dissolution proﬁles
The wettability study indicates that the products containing the
PVP have a more hydrophilic character compared to those with-angles with water were measured for these samples. The contact
angle for the manufacturer NIF (∼81◦) was  relatively high, revea-
ling its poor hydrophilicity. The microwave-assisted crystallization
20 N. Radacsi et al. / Journal of Pharmaceutical an
Table 3
Wettability results for the different NIF samples.
Sample water [◦] diiododmethan [◦]  [mN m−1] Polarity [%]
NIF 81.0 32.4 47.45 16.10
NIF-MW 83.5 38.7 44.78 15.54
NIF-MW-Tconst 72.2 40.5 48.38 25.38
NIF-PVP-MW 55.3 37.7 58.66 34.07
:  contact angle; : surface tension.
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[ig. 5. In vitro dissolution measured at pH 1.2. The amorphous solid dispersion
ample, NIF-PVP-MW, gives the highest dissolution rate.
rom ethanol at maximum microwave power (NIF-MW) did not
hange this character; essentially, the big difference in the particle
ize between NIF and NIF-MW (∼80 m vs. ∼25 m)  did not signif-
cantly change the wettability properties or the polarity. However,
he NIF-MW-Tconst sample showed a more hydrophilic character
nd increased polarity (25.34%). The NIF-PVP-MW turned out to
ave the highest hydrophilicity out of the samples with 55.3◦ water
ontact angle, and also it possesses the highest polarity with 34%.
robably the amorphous nature and the PVP covering a large sur-
ace of the NIF particles are the reasons for the increased wettability
haracter.
Only 10% of NIF was dissolved after 30 min  compared to 20%
nd 27% drug dissolution for NIF-MW and NIF-MW-Tconst, respec-
ively. After 120 min, ∼20% of NIF was dissolved in the medium,
hile both the NIF-MW and NIF-MW-Tconst samples showed ∼50%
f drug dissolution. In the case of the NIF-PVP-MW, 60% of drug was
issolved in the ﬁrst 30 min  and 100% at 120 min. This sample con-
aining PVP consist of amorphous submicron-sized particles, which
re characterized by a higher dissolution rate (Fig. 5.).
Based on the obtained results, the bioavailability of the water
nsoluble crystalline NIF was signiﬁcantly improved. For the fur-
her industrial practical implementation, ab initio calculations
or the characterization of the supramolecular niﬂumic acid:PVP
omplexes resulting in amorphous niﬂumic acid were performed.
ccording to the molecular weight calculation (PVP K-25 (Mw:
4 000)/NIF (Mw: 282.23) the NIF:PVP ratio was 354:1.5. Sekikawa
t al. [22] pointed out that PVP might inhibit the association of
he drug molecule to form the nucleus and inhibit crystal growth.
hus the interaction between the drug and the PVP should be the
nhibitory and/or retarding factor in the crystallization process.
. ConclusionsThis study has shown that microwave-assisted evaporative
rystallization is an effective method to change the physico-
hemical properties of the pharmaceutical active ingredient, NIF.
[d Biomedical Analysis 98 (2014) 16–21
It can be concluded that particle size decrease to micron- and
submicron-size range can be achieved with this procedure. Further,
in the events of microwave-assisted evaporative crystallization
with controlled temperature and or use of PVP, the drug morphol-
ogy changed from rectangular to spherical shape. In the presence
of PVP, as a carrier and crystallization inhibitor, submicron-sized
particles (around 200 nm)  can be produced. According to the struc-
tural analysis, the drug was  in crystalline form without the PVP
excipient and created an amorphous solid dispersion with PVP.
The wettability tests revealed the increased hydrophilicity of the
NIF-MW-Tconst and NIF-PVP-MW samples compared to the NIF-
MW sample or the manufacturer product. The dissolution studies
showed a 2.5-fold increase in the dissolution rate of the produced
NIF crystals compared to the dissolution rate of the original drug in
120 min. The amorphous NIF-PVP-MW sample had a 5-fold increase
in dissolution rate in 120 min  compared to the dissolution of the
crystalline NIF sample.
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